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Abstract
Background: Public health interventions based on distribution of anthelminthic drugs against lymphatic filariasis (LF),
onchocerciasis, soil-transmitted helminthiasis (STH) and schistosomiasis have been implemented separately to date. A
better use of available resources might be facilitated by a more coordinated approach to control such infections, including
the possibility of co-administering the three recommended anthelminthic drugs through a single, large-scale intervention.
Methodology/Principal Findings: Ivermectin, albendazole and praziquantel were co-administered to 5,055 children and
adults living in areas endemic for LF, STH and schistosomiasis in Zanzibar, United Republic of Tanzania, during a pilot
intervention aimed at elucidating and quantifying possible side-effects. Subsequently, these drugs were co-administered to
about 700,000 individuals during a countrywide intervention targeting a large part of the total population of Zanzibar.
Passive and active surveillance measures carried out during both interventions showed that side-effects attributable to the
three drugs given at the same time were mild and self-limiting events.
Conclusions/Significance: Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in
areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several
rounds of treatment with one or two drugs have been implemented in the past. Passive surveillance measures, however,
should be continued and detection, management and reporting of possible side-effects should be considered a key
component of any health intervention administering drugs.
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Introduction
Lymphatic filariasis (LF), soil-transmitted helminthiasis (STH) and
schistosomiasis are diseases of considerable public health importance
in tropical and sub-tropical countries. Globally, 1.2 billion people
live in areas endemic for LF [1] and nearly one-fourth of them may
already have infection [2]. LF is a leading cause of long-term
disability [3]. Schistosomiasis occurs in over 70 countries in the
tropics and sub-tropics; 779 million are estimated to be at risk of
infection and 207 million to be infected [4–6]. 2 billion are estimated
to be infected with STH, namely the roundworm (Ascaris lumbricoides),
the whipworm (Trichuris trichiura), and the hookworms (Ancylostoma
duodenale and Necator americanus), worldwide and several million suffer
from the chronic debilitating morbidity [7–10].
In most endemic countries, these infections often occur in the
same individual [11]. This is especially true in poorest sectors of
the population. Helminth infections have a substantial impact on
the physical and intellectual development and on the overall
health status of infected populations, as well as on the quantity and
quality of their productive work [12–16]. Interventions to tackle
helminth infections and their associated morbidity have been
taken by national programmes in different countries including
Zanzibar, in the United Republic of Tanzania; however such
activities are implemented in a vertical fashion, with different
diseases being addressed separately.
Control of LF, STH and Schistosomiasis in Zanzibar
Zanzibar comprises 2 main islands, Unguja and Pemba, with a
population of around 1.2 million. LF, caused by Wuchereria
bancrofti, and STH and schistosomiasis are considered major public
health problems by the Zanzibar Ministry of Health and Social
Welfare (MoHSW). Transmission of W. bancrofti occurs in both
Unguja and Pemba [17]. Such an epidemiological situation
justifies the inclusion of both islands among the areas eligible for
mass drug administration (MDA) with ivermectin and albendazole
at yearly intervals. Data show that the whole archipelago is also at
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high risk for STH; with the exception of a limited area on Unguja
where the infection is not transmitted, it is also at high risk for
urinary schistosomiasis caused by Schistosoma haematobium (MoHSW
unpublished data, [18–21]). Control of schistosomiasis and STH
through large-scale preventive chemotherapy interventions dis-
tributing praziquantel and albendazole started in 1994. Schools
represented the main delivery channel and schoolchildren the
main target population, however, occasionally whole communities
have been also targeted for treatment. This strategy is still on-
going with a period of interruption of two years (2000 and 2001)
during which activities did not take place due to problems in
securing the drugs. There has been a reduction in prevalence and
intensity of both schistosome and STH infections over the years
(MoHSW unpublished data), however such indicators suggest that
continuation of treatment of schoolchildren is still required. The
last school-based drug distribution before the implementation of
the activities described in this survey was carried out in May 2006.
In 2001 Zanzibar adopted the WHO recommended strategy
against LF, consisting of MDA for elimination as a public health
problem, coupled with disability prevention and management.
MDA in Zanzibar involves administering a once-yearly dose of a
combination of ivermectin (Mectizan, 200 mg/kg) and albendazole
(400 mg) to its entire population, with the exception of those who are
sick or infirm, of children ,90 cm in height, of pregnant women,
and of lactating women in the first week after birth. The last round
before the implementation of the activities described in this article
was conducted in August 2005 (5th round of MDA) [17].
W. bancrofti was highly endemic in both Unguja and Pemba
before MDAs, with a prevalence of microfilaraemia in all age
groups (children and adults) ranging between 5% and 30% [17].
Whilst the evaluation of the impact of MDAs showed an overall
decline in both prevalence and intensity of microfilaraemia, mean
prevalence of infection in all age groups (adults and children) at
one sentinel and in some randomly selected spot-check sites after
the 5th round was still 1% and above. The MoHSW therefore
decided to implement a further round (6th) of MDA. This follows
the WHO recommended processes leading to decision to stop
MDA only after interruption of transmission (prevalence of
microfilaraemia ,1% in the general population) [22].
Triple Drug Co-Administration
The 6th round of MDA for LF offered the opportunity to
evaluate the feasibility and safety of triple drug co-administration
with ivermectin, albendazole and praziquantel in communities
where LF, STH and schistosomiasis are co-endemic.
Ivermectin, albendazole and praziquantel are well suited for
large-scale distribution in helminth control or elimination when
administered individually or in double combination (ivermectin
and albendazole or albendazole and praziquantel) at the
recommended dosages (ivermectin 200 mg/kg; albendazole
400 mg; praziquantel 40 mg/kg). Combination of ivermectin
and albendazole is highly efficacious after a single administration
for LF, and treatment rarely results in side-effects outside those
commonly associated with a therapeutic effect [23]. Similarly, co-
administration of praziquantel and albendazole is an efficacious
and safe tool to control morbidity due to schistosomiasis and STH
in areas where both infections are endemic [24].
However, side-effects do sometimes occur following adminis-
tration of anthelminthic drugs, primarily as a result of the
individual’s immune inflammatory response to dying parasites;
the greater the infection load in the patient, the greater are the
frequency and severity of such reactions. These can include
systemic responses (e..g. headache, myalgia, light-headedness,
anorexia, malaise, nausea, vomiting and wheezing, abdominal
discomfort, dizziness, drowsiness, rectal bleeding); or, less
commonly, localized reactions (including lymphadenitis, funiculi-
tis, epididymitis, lymphangitis and even abscess formation); rarely,
in case of administration of praziquantel for schistosomiasis,
hypersensitivity reactions, fever, pruritus and eosinophilia may
occur. Only seldom (in heavily infected individuals) are these post-
treatment reactions severe or do they require more than just
symptomatic treatment [25].
Triple co-administration of ivermectin, albendazole and
praziquantel has never been carried out in large-scale interven-
tions, however, pharmacokinetic studies performed in healthy (i.e.
non-infected) individuals indicate that there are no pharmacolog-
ical interactions between the three drugs and that triple co-
administration does not enhance their toxicity [26].
However, because of the lack of documentation on such triple
co-administration in real epidemiological scenarios, and consider-
ing that in those settings some of the individuals receiving drugs
may carry high burden of multiple parasites, it is recommended
that triple co-administration is carried out with caution and with
adequate monitoring of potential side-effects [1]. As a first step it is
advisable that in a population that has never been subjected to
MDA with any of these drugs, the initial 1–2 rounds of treatment
with praziquantel should be given separately from ivermectin and/
or albendazole treatment; additionally, in a population that has
previously been subjected to (separate) MDA with either
ivermectin plus praziquantel or ivermectin+albendazole plus
praziquantel, the three drugs should be co-administered in
conjunction with additional safety monitoring for any unantici-
pated side-effects during the initial rounds.
Since in Zanzibar separate MDAs had already been conducted
in the past, it was decided to implement co-administration of the
three drugs with the requisite precautionary measures. Before co-
administering the drugs to the entire eligible Zanzibar population
of around 1 million, it was therefore considered imperative that
such intervention take place in a pilot population and that active
and passive surveillance measures be implemented during and
after treatment.
Results of the pilot intervention were considered crucial to the
initiation of a country-wide intervention. It was agreed that if side
effects during the pilot intervention were mild and transitory, co-
Author Summary
This paper describes how the use of three drugs which are
used separately in mass drug distribution programmes
when given together appear safe for use in large
populations which have been previously treated with the
same drugs separately (Mectizan [ivermectin], albendazole
and praziquantel). The target diseases—lymphatic filariasis,
soil-transmitted worms and schistosomiasis—were preva-
lent in Zanzibar up to 2000 but have been largely
controlled by mass drug administration. The Ministry of
Health and Social Welfare, with the support of WHO,
initiated a small scale trial in a population of triple therapy
in over 5,000 people initially in two sites, and having found
there were no severe adverse events associated with the
combined treatment then upscaled to treat the whole of
the eligible population of over 700,000. Similarly, there
were no severe adverse events. This is the first time the
three drugs have been used together at the same time at
scale in Africa and provide a basis for expansion of
integrated preventive chemotherapy of helminths
(worms). The next steps need to be initiated in populations
which have heavier worm loads and such interventions
need to be subject to close monitoring and ethical review.
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administration would take place throughout Zanzibar and that
active and passive surveillance measures would be also imple-
mented during such a country-wide interventions.
The aim of the present paper is to report on the outcome of
passive and active surveillance measures carried out to elucidate and
quantify any side-effects experienced after co-administration of
ivermectin, albendazole and praziquantel by a sample population of
5,055 and subsequently by about 700,000 individuals living in areas
endemic for LF, STH and schistosomiasis in Zanzibar.
Methods
The Pilot Intervention Study Area
The pilot intervention was conducted in 2 highly endemic sites,
one from each of the two islands forming Zanzibar: Kinyasini
on Unguja (resident population of approximately 4,000) and
Mtambile on Pemba (resident population of approximately 3,000).
Field assessments conducted in all age-groups before the survey
in early November 2006 showed that at Kinyasini prevalence of
LF antigenaemiaia (assessed by an ImmunoChromatographic Test
ICT) [27]) was 4.0%, of urinary schistosomiasis (assessed by urine
filtration) was 63.5% and of STH infections (assessed by Kato-
Katz method) [28] was 76.8%; at Mtambile, these figures were
13.0%, 43.0% and 73.0%, respectively (MoHSW unpublished
data). The major occupations of the community in both sites are
linked to agriculture [29]. Both sites are surrounded by permanent
water bodies.
Criteria for Eligibility
The whole population of both Kinyasini and Mtambile was
considered for enrolment in the pilot intervention. Criteria for
enrolment coincided with criteria for eligibility for administration
of ivermectin and albendazole in LF disease-specific interventions,
which are the most restrictive among the criteria used in
interventions against one of the three diseases (LF, STH, and
schistosomiasis) taken singularly. As such, we considered eligible all
consenting residents of both sites, with the exception of those who
were sick or infirm, of children ,90 cm in height, of pregnant
women, and of lactating women in the first week after birth. All
consenting participants (written and oral) were interviewed in
order to determine their health status before the intervention, and
all their information were recorded.
Drugs and Their Administration
All participants in the study were given their respective dosages
of ivermectin (200 mg/kg), albendazole (400 mg) and praziquantel
(40 mg/kg) at the same time; treatment was directly observed by
drug distributors to ensure that tablets were actually swallowed.
The dosage for ivermectin and praziquantel was calculated using a
two-sided tablet (height) pole that was the combination of the two
poles currently used for separate administration of such drugs
[1,30–32]: one side for determination of the number of ivermectin
tablets and the other side for the number of praziquantel tablets.
The two sides were clearly made distinguishable by the presence of
the Kiswahili (local language) text ‘‘kichocho’’ (schistosomiasis) on
one side and ‘‘matende’’ (elephantiasis, LF) on the other. One
tablet of albendazole (400 mg) was used as the standard dose for
everybody irrespective of age or height [1].
Theoretical and practical training sessions were held during the
weeks preceding the intervention so as to train drug distributors -
who were familiar with single-drug poles - on the use of the two-
sided poles and on the shape and strength of each drug
administered, so as to avoid any risk of miscalculation of the dose
of ivermectin and praziquantel to be administered.
The strategy of drug distribution and the individuals responsible
for drug distribution were the same used in those two sites during
previous interventions of MDA with ivermectin and albendazole
for elimination of LF.
The pilot intervention took place on 18 November at Kinyasini
2006 and on 19 November 2006 at Mtambile.
Surveillance Measures
Both passive and active surveillance measures were implement-
ed during the pilot intervention. Passive measures were aimed at
ensuring rapid medical assistance for any individuals who might
experience side-effects after treatment, while active measures were
in place to elucidate the nature of and quantify any such event.
Passive measures were established on the treatment day and the
day after; two health centres at Kinyasini and two at Mtambile
were kept open round the clock and equipped with first-line
emergency drugs (non-steroid anti-inflammatory drugs, anti-
histaminic drugs, cortisone, intravenous fluids). Individuals who
received drugs were invited to report to these first-line centres in
the event of any side-effects (‘‘anything abnormal occurring in
your body’’), health centre personnel were trained on how to fill in
the record forms and instructed to refer to second-line hospitals
any individual presenting with side effects that they could not
manage. In addition, vehicles/motor bikes patrolled the area to
facilitate a rapid response should it be needed.
Active surveillance measures were also carried out between the
5th and the 7th day after treatment. All treated individuals were
interviewed on occurrence of side-effects by experienced profes-
sional health staff and/or researchers who had participated in
previous health survey studies done in the country and who were
not resident either in Kinyasini or Mtambile. The occurrence of
any side-effects following the ingestion of the three drugs was
investigated. A side-effect was defined as any abnormal event
experienced by a treated individual within period of observation.
A structured questionnaire listing the most common symptoms
and signs usually reported after administration of anthelminthic
drugs was used to record events, but these events were not read to
the interviewee who was asked the following question: ‘‘How have
you been feeling since taking the treatment?’’ and left free to
answer and to grade the possible event as mild, moderate or
severe. For standardization of the approach to be used when
administering the questionnaires,health staff/ researchers received
one day training, on how to ask the questions and fill up the form.
Ethical Clearance
The protocol of the pilot intervention was reviewed and
approved by the Ethical Committee of the Liverpool School of
Tropical Medicine, United Kingdom, and by the MoHSW,
Zanzibar. All individuals participating in the pilot intervention or
their parent/guardian in case of children provided a written
informed consent to treatment. All records are available for
scrutiny in the MoHSW, Zanzibar. The procedure regarding the
administration of questionnaires to designated interviewees was
the same for the pilot project and the nationwide intervention. The
individuals gave consent prior to being interviewed for adverse
events. It is the policy of the MOHSW to obtain consent from
involved communities or involved individuals before carrying out
activities in the field.
Results
Population under Study
A total of 5,055 individuals of both sexes aged 5 years and
above, participated in the pilot intervention: 2,509 from Kinyasini
Triple Drug Co-Administration in Zanzibar
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and 2,546 from Mtambile. The age-group 10–19 years old was the
most represented, in line with current demographic trends in
Tanzania and most developing countries [27]. The number of
females was higher than that of males (Table 1, Figure 1). This can
be mainly explained by the fact that both Kinyasini and Mtambile
are rural areas where young males are either farmers or have
employment in town. Hence, they usually leave their houses early
in the morning and return back late in the evening.
Passive Surveillance Measures
Only 1 treated individual reported to a first-line health centre
(in Kinyasini) complaining about vomiting that started following
treatment; symptoms were, however, mild and successfully
managed on spot without requiring referral to a second-line
hospital facility.
Active Surveillance Measures
The results of the interviews carried between day 5 and 7 post
triple drug administration are shown in Table 2. Overall, a total of
615 events were reported by 504 individuals, i.e. by approximately
10% (504/5055) of those treated. Occurrence of side-effects was
the same (10%) in different sexes and peaked in the age-group
30–39 (Table 2). 87.3% of symptoms occurred within 24 hours of
treatment, while a few were also reported to have occurred on the
second (11.9%) and on the third day (0.8%). The symptom most
frequently reported was dizziness (Table 3). All symptoms were
reported to be mild and subsided within a period of 24 hours after
onset.
The Country-Wide Intervention
As active surveillance for side-effects during the pilot interven-
tion did not indicate any concern, two weeks after co-
administration of the three drugs had taken place in Kinyasini
and Mtambile, on December 2–3, 2006, the first large-scale triple
drug co-administration was carried out in Zanzibar. This
intervention was conducted under the newly established ‘‘Lym-
phatic Filariasis, Schistosomiasis and Soil-Transmitted Helminthi-
asis Integrated Programme’’ of the MoHSW. Every eligible
individual in Zanzibar was targeted to receive the three drugs at
the same time with the exception of those living in areas without
transmission of schistosomiasis where only ivermectin and
albendazole were administered. Such areas are restricted to
Unguja island and include the whole Urban district of Stone
Town, the whole South district, and some communities (shehias) in
the North A district [18–20]. The same criteria for eligibility and
ineligibility were applied as in the pilot intervention. Overall,
about 700,000 individuals were administered three drugs (iver-
mectin, albendazole and praziquantel) and another 300,000 two
drugs (ivermectin and albendazole).
Table 1. Population participating in the pilot intervention.
Treated population
Age group Total Female Male
,10 763 (15.1%) 455 308
10–19 1548 (30.6%) 885 663
20–29 890 (17.6%) 609 281
30–39 696 (13.8%) 477 219
40–49 538 (10.6%) 327 211
50+ 620 (12.3%) 398 222
Total 5055 (100%) 3151 (62.3%) 1904 (37.7%)
doi:10.1371/journal.pntd.0000171.t001
Table 2. Age distribution of individuals reporting side-effects.
Age Group Female Male Total
,10 19/455 (4.2%) 17/308 (5.5%) 36/763 (4.7%)
10–19 76/885 (8.6%) 50/663 (7.5%) 126/1548 (8.1%)
20–29 59/609 (9.7%) 32/281 (11.4%) 91/890 (10.2%)
30–39 85/477 (17.8%) 34/219 (15.5%) 119/696 (17.1%)
40–49 27/327 (8.3%) 28/211 (13.3%) 55/538 (10.2%)
50+ 48/398 (12.0%) 29/222 (13.0%) 77/620 (12.4%)
Total 314/3151 (10%) 190/1904 (10%) 504/5055 (10%)
doi:10.1371/journal.pntd.0000171.t002
Table 3. Nature and timeline of side-effects during the pilot
intervention.
Symptoms
Day
1
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7 Total
Fever 15 6 3 0 0 0 0 24
Headache 59 8 1 0 0 0 0 68
Dizziness 160 13 1 0 0 0 0 174
Nausea 97 5 0 0 0 0 0 102
Vomiting 12 0 0 0 0 0 0 12
Diarrhoea 23 9 0 0 0 0 0 32
Abdominal Pain 106 21 0 0 0 0 0 127
Joint/Muscle Pain 19 2 0 0 0 0 0 21
Fatigue 24 7 0 0 0 0 0 31
Swelling of the limbs 0 2 0 0 0 0 0 2
Swelling of scrotum 0 0 0 0 0 0 0 0
Scrotal Pain 2 0 0 0 0 0 0 2
Rash 3 0 0 0 0 0 0 3
Itching 8 0 0 0 0 0 0 8
Others 9 0 0 0 0 0 0 9
Total 537 73 5 0 0 0 0 615
doi:10.1371/journal.pntd.0000171.t003
Figure 1. Population participating in the pilot intervention.
doi:10.1371/journal.pntd.0000171.g001
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As in the pilot intervention, the door-to-door strategy was
chosen as the method of drug administration. For effective
coverage, 4,161 drug distributors, used in previous LF-MDA
interventions, were deployed and given extra training on how to
use the two–sided drug pole in determining number of tablets.
Each drug distributor was responsible for 50 households. All drug
distributors were previously identified through a community-based
participatory process, so as to guarantee their full acceptance by
populations targeted. Many of them were health personnel or
school teachers.
Zanzibar was divided into 14 MDA operational units – 9 of the
units followed the administrative divisions (districts); 3 were the
result of subdividing the urban districts into more manageable
units; and the remaining 2 units targeted special groups within
special institutions (SI) (soldiers, policemen, prisoners, etc.).
The social mobilization component was given high priority in
the campaign. Three important areas were emphasized:
1. The use of drug distributors to carry out social mobilisation
through two preparatory visits to the households. The
distributor explained the rationale of the programme and
prepared people for any potential side-effects; in addition, these
visits were also intended to build rapport and confidence
between the distributors and the household members.
2. The proactive involvement of the religious and political leaders
of different parties, at national, regional, district and commu-
nity level.
3. The effective use of mass media and other communication
tools.
Similar to what had happened for the pilot intervention, both
passive and active surveillance measures were taken during and
after the country-wide drug administration. Passive surveillance
was established during the intervention through the network of
health centres and referral hospitals in both islands to monitor and
respond to potential side-effects.
One week after the drug distribution, active surveillance
measures were carried out to quantify the occurrence of side-
effects in a sub-sample of the target population; the activity was
incorporated into the routine survey intended to assess and check
drug coverage. 35 communities (shehias) out of the 250 that form
Zanzibar were randomly selected (20 in Unguja and 15 in
Pemba), and 600–1000 people per site were interviewed, for a
total of 19,043 individuals. A researcher was randomly assigned
to each of the 35 evaluation sites and entered houses following a
random route in their area. The same questionnaire as in the
pilot intervention was used, and each individual visited was
interviewed to check drug intake and investigate side-effects
experienced.
Results
Overall, only 266 individuals, equivalent to 1.4% of the
interviewees who swallowed the drugs reported any side-effects,
none of which was judged to be significant enough to justify a visit
to the nearest health centre. All the side-effects were mild, the most
frequent being fatigue (n = 102), abdominal pain (n = 67), dizziness
(n = 57), fever (n = 27) and vomiting (n = 13). These side-effects
were accepted and managed by those who reported them. They
were transient and all counted for less than 24 hours. No
difference in nature and frequency of side-effects was documented
during the country-wide intervention between areas where
ivermectin and albendazole only were distributed and areas where
praziquantel was also added to the package.
Discussion
The results of the pilot intervention in Kinyasini and Mtambile
were considered representative of the worst possible epidemiolog-
ical scenarios in Zanzibar and as such were deemed sufficient to
justify the implementation of the first nationwide intervention, in
which ivermectin and albendazole currently recommended for
elimination of LF and praziquantel for control of schistosomiasis
were administered at the same time. The first national scale triple
therapy carried out in Africa or indeed globally.
Passive and active surveillance measures implemented during
both the pilot and the country-wide intervention showed that side-
effects experienced by individuals co-administered with the three
drugs were mild and self-limiting events. It was not possible or
feasible to obtain individual data on parasitological status hence
this data does not allow us to establish a clear relationship between
infection status and side-effects experienced. However, we believe
that our data show that triple drug co-administration is a feasible
option in real epidemiological scenarios such as those exemplified
by Kinyasini and Mtambile, where pre-intervention prevalence
rates for schistosomiasis and STH infections were high and where
W. bancrofti micrfilaria prevalence remained above the 1% cut off
point for MDA [17]. The studies using the ICT cards to measure
antigenaemia have limited value at this stage of an LF programme
as they only measure the presecnec of adult worm antigen. Their
use and value in post MDA evaluation is in measuring the
transmission to children born since the first MDA commenced.
The proportion of individuals reporting any side-effects in the
pilot intervention phase (10%) is higher than that in the
nationwide intervention phase (1.4%). This can be explained by
the fact that Kinyasini and Mtambile are both sites with
particularly high prevalence of helminthic infections, while the
nationwide intervention also covered areas with lower prevalence.
The two sites were specifically selected in order to assess the
occurrence of side-effects in places where they are expected to be
most frequent and most severe, so as to use the results of the pilot
intervention as indicators and make a judgment before the
implementation of the nationwide intervention. It is also possible,
however, that the sensitivity of the surveillance system during the
pilot intervention was higher than during the nationwide
intervention: individuals responsible for surveillance during the
pilot intervention - which had a research-like outlook - might have
paid more attention to recording side-effects.
Overall, both in the pilot and the nationwide intervention, the
number of individuals reporting side-effects following treatment
registered a significant decline from that reported for distribution of
ivermectin and albendazole only by 2002 (24%) [33], which could be
explained by considering that the average wormload in infected
individuals in 2002 may have been higher due to the fact that only
two rounds of LF treatment had taken place, and in the two previous
years (2000 and 2001) the second yearly round of albendazole for
STH had not been implemented due to shortage of drugs.
Data from such a large population under study in Zanzibar
therefore suggests that co-administration of the three drugs is a safe
intervention when carried out in an area where LF, STH and
schistosomiasis are co-endemic and where several rounds of
treatment with one or two drugs have been implemented in the past.
However, it is necessary to emphasize the need for maintaining
passive surveillance measures during similar interventions, and to
ensure that detection, management and reporting of potential side-
effects are a key component of any health intervention
administering drugs [34].
There are opportunities arising from a coordinated approach to
tackle multiple tropical diseases simultaneously. Currently many
Triple Drug Co-Administration in Zanzibar
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control/elimination programmes in Africa are constrained not by
drug availability but by lack of the financial resources necessary for
drug distribution, and it is expected that distribution costs will be
lower when drugs are co-administered than in the case when
several ‘‘vertical’’ interventions are conducted separately [35–38].
Meeting distribution costs would mean being able to implement
control activities, since ivermectin and albendazole for LF
elimination are donated. Praziquantel is not at presented donated
on adequate scale to cover all the current needs.
In countries where there is a significant overlap between LF,
STH and schistosomiasis [1], triple drug co-administration can be
an option to cut down costs, boost control activities and improve
the health status of neglected populations. Co-administration of
anthelminthic drugs also offers an opportunity for integration of
parasitic disease control programmes into the regular health
system activities in Africa and elsewhere which has an appeal for
most partners or donors. These interventions provide many
benefits beyond purely disease elimination or control as they are
relevant to the millennium development goals. MDA is a pro- poor
non – discriminatory, and hence equitable intervention which
reaches all eligible people irrespective of socio-economic status.
This paper demonstrates co – administration of three highly
efficacious antihelminthic drugs can be achieved at scale with very
limited but acceptable side-effects. This work will pave the way for
the next stage of studies in more intensely infected populations.
This result will permit further expansion of the WHO policy of
preventive chemotherapy [1] to needy populations for the control
of neglected tropical diseases in sub Saharan Africa where
extensive co-endemicity is the norm rather than the exception.
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